Wave Life Sciences Ltd. (WVE)

NASDAQ: WVE · IEX Real-Time Price · USD
6.23
-0.25 (-3.86%)
At close: Jun 14, 2024, 4:00 PM
6.05
-0.18 (-2.89%)
After-hours: Jun 14, 2024, 7:22 PM EDT
-3.86%
Market Cap 762.93M
Revenue (ttm) 112.91M
Net Income (ttm) -61.92M
Shares Out 122.46M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 338,032
Open 6.41
Previous Close 6.48
Day's Range 6.15 - 6.41
52-Week Range 3.45 - 7.67
Beta -1.04
Analysts Strong Buy
Price Target 12.29 (+97.27%)
Earnings Date Aug 1, 2024

About WVE

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for t... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 11, 2015
Employees 266
Stock Exchange NASDAQ
Ticker Symbol WVE
Full Company Profile

Financial Performance

In 2023, WVE's revenue was $113.31 million, an increase of 3005.10% compared to the previous year's $3.65 million. Losses were -$57.51 million, -64.46% less than in 2022.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for WVE stock is "Strong Buy." The 12-month stock price forecast is $12.29, which is an increase of 97.27% from the latest price.

Price Target
$12.29
(97.27% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing

Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave's INHBE program as a best-in-class approach for obesity...

2 days ago - GlobeNewsWire

Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...

15 days ago - GlobeNewsWire

Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD remains on track for 2024

5 weeks ago - GlobeNewsWire

Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

Appointment builds on Wave's recent progress advancing innovative genetic targets, such as INHBE, and continues to add significant experience to accelerate the rapid identification and translation of ...

5 weeks ago - GlobeNewsWire

Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference

CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...

5 weeks ago - GlobeNewsWire

Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...

6 weeks ago - GlobeNewsWire

Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)

Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024 Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024

6 weeks ago - GlobeNewsWire

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNA...

7 weeks ago - GlobeNewsWire

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...

2 months ago - GlobeNewsWire

Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-s...

3 months ago - GlobeNewsWire

Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

3 months ago - GlobeNewsWire

Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy

Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which are important for potential muscle regeneration

3 months ago - GlobeNewsWire

Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones

Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans

5 months ago - GlobeNewsWire

Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling d...

5 months ago - GlobeNewsWire

Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy

FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024 Previous clinical proof-of-concept data demonstrated highest level of exon skipping ever observ...

6 months ago - GlobeNewsWire

Wave Life Sciences stock slides 31% after company prices $100 million secondary share offering

Wave Life Sciences Ltd.'s stock WVE, -30.57% tumbled 31% Thursday, after the clinical-stage pharma company priced a $100 million secondary share offering at $5 a share, or a discount over its closing ...

6 months ago - Market Watch

Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares

CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling d...

6 months ago - GlobeNewsWire

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling d...

6 months ago - GlobeNewsWire

Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency

Wave Life Sciences Announces Initiation of Dosing in Clinical Trial Evaluating First-Ever RNA Editing Candidate, WVE-006, in Alpha-1 Antitrypsin Deficiency

6 months ago - GlobeNewsWire

Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling d...

7 months ago - GlobeNewsWire

Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Initiated RestorAATion clinical program for WVE-006, industry's first-ever RNA editing clinical candidate, following approval of CTAs; dosing on track for 4Q 2023 and first-in-human proof-of-mechanism...

7 months ago - GlobeNewsWire

Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling d...

8 months ago - GlobeNewsWire

Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day

Presented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disorders, including obesity, which uses Wave's best-in-class GalNAc-siRNA capabilities and nove...

9 months ago - GlobeNewsWire

Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling ...

9 months ago - GlobeNewsWire

Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling ...

10 months ago - GlobeNewsWire